Table 2. Symptom score and spirometric pulmonary function changes after the 3-month treatment according to the baseline mMRC dyspnea scale.
| Variables | mMRC 0 or 1 (n=62) | mMRC ≥2 (n=40) | P value |
|---|---|---|---|
| Symptom changes after 3-month treatment | |||
| mMRC dyspnea scale | 0.11±0.07 | −0.65±0.13 | <0.001 |
| Proportion of patients with a mMRC change ≥−1 (n, %) | 3 (4.8%) | 20 (50%) | <0.001 |
| CAT score | −1.39±0.47 | −2.63±0.52 | 0.09 |
| Proportion of patients with a CAT score change ≥−2 (n, %) | 30 (48.4%) | 23 (57.5%) | 0.420 |
| Spirometric pulmonary function changes after 3-month treatment | |||
| FEV1 change (mL) | 113±34 | 102±28 | 0.814 |
| FEV1 change (% predicted) | 3.7±1.2 | 3.3±0.9 | 0.841 |
| FEV1 change (% baseline) | 8.0±2.2 | 8.7±2.5 | 0.851 |
| FVC change (mL) | 122±46 | 90±57 | 0.661 |
| FVC change (% predicted) | 2.9±1.1 | 2.1±1.3 | 0.644 |
| FVC change (% baseline) | 4.1±1.4 | 3.2±1.8 | 0.704 |
Data are presented as the number of patients or the mean ± SEM. mMRC, Modified Medical Research Council; CAT, COPD Assessment Test; SGRQ, St. George’s Respiratory questionnaire; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.